Skip to main content
    I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.65
    +0.05 (+3.13%)

    Market Cap: $44.41M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(18/31)
    Avg Surprise
    -53.93%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.20 - $-0.17
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.17-12.1%
    60d ago$-0.17-12.1%
    30d ago$-0.17-12.1%
    7d ago$-0.180.0%
    Current$-0.18
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.10 - $0.14
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.18---
    Jun 26
    Reported Aug 6
    		$-0.05N/A+75.00%Beat+85.3%
    Mar 26
    Reported May 7
    		$-0.20$-0.18-11.11%Miss+53.5%
    Dec 25
    Reported Mar 30
    		$-0.18$-0.27+33.33%Beat+55.0%
    Sep 25
    Reported Oct 30
    		$-0.24$-0.32+25.00%Beat+60.0%
    Jun 25
    Reported Aug 7
    		$-0.34$-0.37+8.11%Beat+32.0%
    Mar 25
    Reported May 8
    		$-0.43$-0.45+4.44%Beat+29.5%
    Dec 24
    Reported Mar 27
    		$-0.40$-0.54+25.93%Beat+14.9%
    Sep 24
    Reported Oct 31
    		$-0.60$-0.49-22.45%Miss-25.0%
    Jun 24
    Reported Aug 1
    		$-0.50$-0.62+19.35%Beat-38.9%
    Mar 24
    Reported May 9
    		$-0.61$-0.52-17.31%Miss-69.4%
    Dec 23
    Reported Mar 28
    		$-0.47$-0.44-6.82%Miss-46.9%
    Sep 23
    Reported Nov 1
    		$-0.48$-0.40-20.00%Miss-11.6%
    Jun 23
    Reported Aug 7
    		$-0.36$-0.38+5.26%Beat+5.3%
    Mar 23
    Reported May 3
    		$-0.36$-0.02-1700.00%Miss+7.7%
    Dec 22
    Reported Mar 2
    		$-0.32$-0.48+33.33%Beat+41.8%
    Sep 22
    Reported Nov 2
    		$-0.43$-0.52+17.31%Beat+21.8%
    Jun 22
    Reported Aug 3
    		$-0.38$-0.47+19.15%Beat+13.6%
    Mar 22
    Reported May 5
    		$-0.39$-0.60+35.00%Beat-21.9%
    Dec 21
    Reported Mar 3
    		$-0.55$-0.58+5.17%Beat-111.5%
    Sep 21
    Reported Nov 3
    		$-0.55$-0.40-37.50%Miss-52.8%
    Jun 21
    Reported Aug 4
    		$-0.44$-0.34-29.41%Miss-120.0%
    Mar 21
    Reported May 5
    		$-0.32$-0.28-14.29%Miss-68.4%
    Dec 20
    Reported Mar 4
    		$-0.26$-0.31+16.13%Beat-18.2%
    Sep 20
    Reported Nov 5
    		$-0.36$-0.17-111.76%Miss-28.6%
    Jun 20
    Reported Aug 5
    		$-0.20$-0.23+13.04%Beat-5.3%
    Mar 20
    Reported May 14
    		$-0.19$-0.21+9.52%Beat+5.0%
    Dec 19
    Reported Mar 11
    		$-0.22$-0.25+12.00%Beat-4.8%
    Sep 19
    Reported Nov 8
    		$-0.28$-0.19-47.37%Miss-600.0%
    Jun 19
    Reported Aug 9
    		$-0.19$-0.20+5.00%Beat+65.5%
    Mar 19
    Reported May 15
    		$-0.20$-0.19-5.26%Miss+20.0%
    Dec 18
    Reported Mar 29
    		$-0.21$-0.19-10.53%Miss-600.0%
    Sep 18
    Reported Dec 21
    		$-0.04$0.00N/AMiss-
    Jun 18
    Reported Aug 30
    		$-0.55$0.00N/AMiss-
    Mar 18
    Reported Jun 13
    		$-0.25$0.00N/AMiss-
    Sep 17
    Reported Dec 1
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.46EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-74.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.04xQuick Ratio4.04x
    Trading Statistics
    Beta0.90Avg Volume368.32K
    52-Week High$2.6052-Week Low$1.09

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.80
    SMA 20$1.93
    SMA 50$2.12
    SMA 200$1.64
    EMA 10$1.78
    EMA 20$1.90
    EMA 50$1.98
    EMA 200$2.02

    MACD

    Line: -0.13Signal: -0.10Hist: -0.03

    ADX

    ADX: 29.8+DI: 15.9-DI: 30.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.92

    Bollinger Bands

    Upper Band$2.31
    Lower Band$1.56
    %B Position3857%(Upper)
    Band Width0.12

    RSI (14-Day)

    Neutral
    32.3

    Momentum Oscillators

    Stoch %K11.8
    Stoch %D8.3
    Williams %R-76.7
    ROC (10d)-14.5%
    Momentum-0.28
    CCI (20d)-164.4
    MFI (14d)9.0

    Volatility Measures

    ATR (14d)$0.14(8.2%)
    StdDev (20d)0.19
    Hist Vol56.0%(High)

    Volume Flow

    VWAP$1.62
    OBV-58.6M
    AD Line-34.1M
    CMF (20d)-0.299

    Volume Metrics

    Avg Vol (20d)337.9K
    Vol Ratio1.9x(High)
    VWMA (20d)$1.91

    Pivot Points

    R3$2.14
    R2$2.03
    R1$1.81
    Pivot Point$1.70
    S1$1.49
    S2$1.38
    S3$1.16

    Advanced Oscillators

    TSI-27.83
    Ultimate Osc33.5
    KST-183.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$50,000$0$0$0$14,000$28,000$43,000
    Cost of Revenue$0$0$56,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-56,000$0$0$50,000N/A$0$0$14,000$28,000$43,000
    Operating Expenses$1.48M$5.81M$5.47M$7.43M$24.57M$9.96M$9.47M$12.29M$9.87M$11.03M$8.41M$8.57M
    R&D$-803,000$3.64M$2.33M$4.89M$5.80M$7.64M$7.35M$10.07M$7.05M$8.69M$6.01M$5.99M
    SG&A$2.28M$2.17M$3.15M$2.55M$2.25M$2.32M$2.11M$2.22M$2.81M$2.34M$2.40M$2.59M
    Operating Income$-1,476,000$-5,812,000$-5,474,000$-7,433,000$-24,571,000$-9,905,000$-9,467,000$-12,286,000$-9,865,000$-11,017,000$-8,379,000$-8,528,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$8,000$29,000$35,000
    Income Before Tax$-1,273,000$-5,407,000$-5,264,000$-6,472,000$-24,458,000$-9,739,000$-9,218,000$-12,093,000$-9,746,000$-11,025,000$-8,408,000$-8,563,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,273,000$-5,407,000$-5,264,000$-6,472,000$-24,458,000$-9,739,000$-9,218,000$-12,093,000$-9,746,000$-11,025,000$-8,408,000$-8,563,000
    EBITDA$-1,207,000$-5,760,000$-5,418,000$-7,433,000$-24,458,000$-9,905,000$-9,461,000$-12,271,000$-9,841,000$-10,991,000$-8,334,000$-8,474,000
    EBIT$-1,273,000$-5,812,000$-5,474,000$-7,433,000$-24,458,000$-9,905,000$-9,467,000$-12,286,000$-9,865,000$-11,025,000$-8,379,000$-8,528,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INMB

    News

    INmune Bio Inc. (INMB) Partners With QCi to Apply Quantum/AI to XPro Research

    INmune Bio Inc. (INMB) has partnered with Quantum Computing Inc. (QCi) to utilize quantum optimization, AI, and analytics in its research for XPro. The collaboration aims to identify new indications and prioritize...

    TradingView•10/16/26•Somewhat-Bullish

    INmune Bio stock sits 36.15 percent below its Nasdaq high

    INmune Bio stock is currently trading 36.15 percent below its 52-week Nasdaq high, with a market capitalization of USD 46.1 million as of October 15, 2026. The stock, which closed at EUR 1.48 on October 15, 2026...

    ad-hoc-news.de•10/15/26•Neutral

    QCi and INmune Bio partner to study XPro in Alzheimer’s

    INmune Bio and Quantum Computing (QCi) have formed a partnership to use quantum computing, AI, and data analytics to explore new indications for XPro...

    Yahoo Finance•10/15/26•Bullish

    Quantum Computing Inc Expands Into Pharma With INmune Bio Deal

    Quantum Computing Inc. (QCi) is expanding into the pharmaceutical sector through a collaboration with INmune Bio. The partnership will utilize QCi's Dirac-3S quantum optimization machine to analyze clinical data from...

    Quantum Zeitgeist•10/15/26•Bullish

    INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro

    INmune Bio Inc. and Quantum Computing Inc. announced a collaboration to use quantum computing, AI, and data analytics to discover new applications for INmune Bio's investigational Alzheimer's treatment...

    TradingView•10/14/26•Bullish

    INMB Valuation and Fair Value

    P/E
    -2.5x
    P/B
    2.2x
    See GNG's fair value

    INMB Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -74.8%

    INMB Competitors

    CompanyTicker
    Xtant Medical Holdings IncXTNT
    Serina Therapeutics IncSER
    Celularity IncCELU
    Rapid Micro Biosystems IncRPID
    LAVA Therapeutics NVLVTX
    Dogwood Therapeutics, Inc.DWTX
    Hyperion DeFi, Inc.HYPD
    eXoZymes, Inc.EXOZ

    Sector: Healthcare

    INMB Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    INMB Bull Case vs Bear Case

    Bull case

    • INMB beat EPS estimates in 75.0% of its last 8 reported quarters.
    • INMB grew quarterly revenue 257.1% year over year.

    INMB Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    17.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.18
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About INMB

    Does INMB pay dividends?

    INmune Bio Inc (INMB) does not currently pay a regular dividend.

    What is INMB's market cap?

    INmune Bio Inc (INMB) has a market capitalization of $44.41M with a current stock price of $1.65.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In